Sign in Subscribe
Genetic research

Researchers Identify Clinically Relevant Profiles in Colon Cancer Through Integrated Analysis of Bacterial DNA and Metabolome

Strategic Insights

— 1 min read

Researchers from Complutense University have made a significant breakthrough in understanding the relationship between microbiota and colorectal cancer. The study, published in Frontiers in Immunology, aimed to identify serum biomarkers for the diagnosis of colorectal cancer. By analyzing bacterial DNA and metabolomic profiles in 64 serum samples from patients with colon cancer and controls, the team discovered different profiles between the two groups, with serum levels of Firmicutes and threonic acid being the most relevant characteristics that could help differentiate between the two.

Key Takeaways:

  • The study was conducted by a team of researchers from Complutense University, led by Juan Vicente-Valor, and included co-authors Sofia Tesolato, Dulcenombre Gomez-Garre, Mateo Paz-Cabezas, Adriana Ortega-Hernandez, Constanza Fernandez-Hernandez, Sofia de la Serna, Inmaculada Dominguez-Serrano, Jana Dziakova, Daniel Rivera, Francisco-Javier Ruperez, Antonia Garcia, Antonio Torres, and Pilar Iniesta.
  • The researchers analyzed bacterial DNA and metabolomic profiles in 64 serum samples from patients with colon cancer and controls using metagenomic analysis and Gas Chromatography-Quadruple Time-Of-Flight Mass Spectrometry.
  • The study found different profiles in the colon cancer population and controls, regardless of age, gender, and body mass index.
  • Serum levels of Firmicutes and threonic acid were found to be the most relevant characteristics that could help differentiate between the two groups, achieving an excellent predictive accuracy in the discovery cohort (area under the ROC curve = 0.95).
  • The study's findings suggest that serum biomarkers could be relevant and applicable to the early diagnosis of colon cancer.

Statistics:

  • 64 serum samples were analyzed in the study.
  • Serum levels of Firmicutes were found to be significantly different between the colon cancer population and controls (p < 0.001).
  • The area under the ROC curve for predicting colon cancer was 0.95, indicating excellent predictive accuracy.
  • 16S rRNA gene in serum was analyzed using metagenomic analysis.

Sources:

  • Frontiers in Immunology, "Identification of clinically relevant profiles in colorectal cancer through integrated analysis of bacterial DNA and metabolome in serum."
  • Complutense University, "Research on Colon Cancer by Juan Vicente-Valor and team."
  • NewsRx, "Complutense University Researchers Yield New Study Findings on Colon Cancer."

Read more